SFS
BCLI

Sowell Financial Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sowell Financial Services’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30
Closed -$1K – 740
2021
Q1 		$1K Sell
30
-1
-3% -$76 ﹤0.01% 2902
2020
Q4 		$2K Sell
31
-22
-42% -$3K ﹤0.01% 2444
2020
Q3 		$13K Hold
53
– – ﹤0.01% 1719
2020
Q2 		$9K Buy
53
+21
+66% +$2.26K ﹤0.01% 1718
2020
Q1 		$2K Buy
32
+25
+357% +$1.95K ﹤0.01% 2042
2019
Q4 		$0 Buy
+7
New +$406 ﹤0.01% 2512

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sowell Financial Services's BCLI Position: Q2 2021 in Review

Sowell Financial Services sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 30 shares — an estimated $1K sold.

Sowell Financial Services first reported a position in BCLI in Q4 2019 and held it in 6 quarters. The position peaked at $13K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Sowell Financial Services reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Sowell Financial Services sold 30 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $1K.
  • Sowell Financial Services first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2019 and held it in 6 quarters.
  • Sowell Financial Services's BRAINSTORM CELL THERAPUTC position peaked at $13K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Sowell Financial Services's 13F filing for Q2 2021, filed 5 Aug 2021.